ATHE סך נכסי הפעילות העסקית Alterity Therapeutics Ltd

Alterity Therapeutics focuses on developing treatments for rare brain pathologies, mitigating risks through a broad portfolio of molecules. The strategy relies on partnerships with leading scientific centers dedicated to combating neuronal degeneration. Current R&D status and the absence of sales are driving cost increases, which is reflected in the market value dynamics of the asset on GURU.Markets, where total assets amount to 31.03.

Total assets reflect the aggregate value of the company's resources, calculated reverse-engineered via return on assets (ROA) to eliminate reporting time lags. Analyzing the aggregate resources of Alterity Therapeutics (ATHE) allows for an assessment of its financial stability, which is critical given the high dependence on external contract laboratories and the difficulty of switching vendors due to stringent regulatory restrictions.